NCT00795821

A Study in Adult Patients With Major Depressive Disorder

A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 495 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	LY2216684	Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
DRUG	Placebo	Dose: 3 tablets QD for 10 weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-02-01
• Completion: 2011-03-01
• First posted: 2008-11-21
• Last updated: 2018-03-20
• Results posted: 2018-03-20

Locations

37 sites across 5 countries: United States, Argentina, Finland, Poland, Russia